CAMBRIDGE, Mass., July 27, 2022 /PRNewswire/ — QurAlis Corporation, a biotechnology company developing breakthrough precision drugs for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, announced today that Kasper RoetPh.D., Founder and CEO, will present at the HC Wainwright Private Company Showcase the Wednesday, August 3, 2022 at 2:50 p.m. ET.
QurAlis’ corporate presentation can be accessed by visiting the presentations section of the Company’s website at www.quralis.com.
About QurAlis Corporation
QurAlis paves the way to conquer amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation precision drugs. QurAlis’ proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on pathogenic genetic alterations. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing an extensive pipeline of antisense oligonucleotides and small molecule programs, including addressing the subforms of ALS that represent the majority of ALS patients. For more information, please visit www.quralis.com or follow us on Twitter @QurAlisCo.
View original content to download multimedia: https://www.prnewswire.com/news-releases/quralis-to-present-at-hc-wainwright-private-company-showcase-301592758.html